Bortezomib reverses a post-translational mechanism of tumorigenesis for Patched1 haploinsufficiency in medulloblastoma

Pediatric Blood and Cancer

Volumn 53, Issue 2, 2009, Pages 136-144

  Taniguchi, Eri ^a   Min, Jung Cho ^a   Arenkiel, Benjamin R ^b   Hansen, Mark S ^b   Rivera, Omar J ^a   McCleish, Amanda T ^a   Qualman, Stephen J ^c   Guttridge, Denis C ^d   Scott, Matthew P ^e   Capecchi, Mario R ^b   Keller, Charles ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Bortezomib; Haploinsufficiency; Hedgehog; Medulloblastoma; Patched1; Proteasome

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR PAX7; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; ISOPROTEIN; PATCHED RECEPTORS; PAX7 PROTEIN, MOUSE; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CEREBELLUM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE DOSAGE; GENE INACTIVATION; HAPLOIDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEINASE INHIBITION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; ANIMAL; CELL TRANSFORMATION; CEREBELLUM TUMOR; DISEASE MODEL; GENE TARGETING; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CEREBELLAR NEOPLASMS; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HEDGEHOG PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LOSS OF HETEROZYGOSITY; MEDULLOBLASTOMA; MICE; MICE, KNOCKOUT; PAX7 TRANSCRIPTION FACTOR; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; RECEPTORS, CELL SURFACE;

EID: 67650002395     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21968     Document Type: Article

References (39)

1. Knudson AG, Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
2. Cook DL, Gerber AN, Tapscott SJ. Modeling stochastic gene expression: Implications for haploinsufficiency. Proc Natl Acad Sci USA 1998;95:15641-15646. (Pubitemid 29018753)
3. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: When you don't need to go all the way. Biochim Biophys Acta 2004;1654:105-122. (Pubitemid 38681204)
4. Oliver TG, Read TA, Kessler JD, et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005;132:2425-2439.
5. Kim JY, Nelson AL, Algon SA, et al. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol 2003;263:50-66.
6. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-240.
7. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 2000;60:2239-2246. (Pubitemid 30225189)
8. Zurawel RH, Allen C, Wechsler-Reya R, et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000;28:77-81. (Pubitemid 30176765)
9. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-1561.
10. Uhmann A, Ferch U, Bauer R, et al. A model for PTCH1/Ptch1-associated tumors comprising mutational inactivation and gene silencing. Int J Oncol 2005;27:1567-1575.
11. Kogerman P, Krause D, Rahnama F, et al. Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein. Oncogene 2002;21:6007-6016.
12. Nagao K, Toyoda M, Takeuchi-Inoue K, et al. Identification and characterization of multiple isoforms of a murine and human tumor suppressor, patched, having distinct first exons. Genomics 2005;85:462-471. (Pubitemid 40386475)
13. Shimokawa T, Svard J, Heby-Henricson K, et al. Distinct roles of first exon variants of the tumor-suppressor Patched1 in Hedgehog signaling. Oncogene 2007;26:4889-4896. (Pubitemid 47172648)
14. Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. EMBO J 2004;23:3430-3439. (Pubitemid 39209166)
15. Mansour SL, Thomas KR, Capecchi MR. Disruption of the protooncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 1988;336:348-352.
16. Rodriguez CI, Buchholz F, Galloway J, et al. High-efficiency deleter mice show that FLPe is an alternative to Cre- loxP [letter]. Nat Genet 2000;25:139-140. (Pubitemid 30394979)
17. Keller C, Hansen MS, Coffin CM, et al. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: Implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004;18:2608-2613. (Pubitemid 39453100)
18. Shimokawa T, Rahnama F, Zaphiropoulos PG. A novel first exon of the Patched1 gene is upregulated by Hedgehog signaling resulting in a protein with pathway inhibitory functions. FEBS Lett 2004;578:157-162. (Pubitemid 39576118)
19. Srinivas S, Watanabe T, Lin CS, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 2001;1:4. (Pubitemid 38883775)
20. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513-516. (Pubitemid 32128609)
21. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-425. (Pubitemid 34326692)
22. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-1113. (Pubitemid 27371635)
23. Uchikawa H, Toyoda M, Nagao K, et al. Brain- and heart-specific Patched-1 containing exon 12b is a dominant negative isoform and is expressed in medulloblastomas. Biochem Biophys Res Commun 2006;349:277-283. (Pubitemid 44339629)
24. Lu X, Liu S, Kornberg TB, et al. C-terminal tail of the Hedgehog receptor Patched regulates both localization and turnover. Genes Dev 2006;20:2539-2551. (Pubitemid 44396839)
25. Herrmann JL, Briones F, Jr., Brisbay S, et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998;17:2889-2899. (Pubitemid 29010059)
26. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076. (Pubitemid 32691956)
27. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-354. (Pubitemid 40188583)
28. Goodrich LV, Johnson RL, Milenkovic L, et al. Conservation of the hedgehog/patched signaling pathway from flies to mice induction of a mouse patched gene by Hedgehog. Genes Dev 1996;10:301-312. (Pubitemid 26058963)
29. Chauhan D, Hideshima T, Mitsiades C, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-692. (Pubitemid 40601851)
30. Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007;104:8455-8460. (Pubitemid 47175509)
31. Sanchez P, Ruiz I Altaba A. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech Dev 2005;122:223-230.
32. Ellis T, Smyth I, Riley E, et al. Patched 1 conditional null allele in mice. Genesis 2003;36:158-161. (Pubitemid 36959347)
33. Uhmann A, Dittmann K, Nitzki F, et al. The Hedgehog receptor Patched controls lymphoid lineage commitment. Blood 2007;110:1814-1823. (Pubitemid 47443892)
34. Mak KK, Chen MH, Day TF, et al. Wnt/beta-catenin signaling interacts differentially with Ihh signaling in controlling endochondral bone and synovial joint formation. Development 2006;133:3695-3707.
35. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008;14:135-145.
36. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000;27:44-51.
37. Mao J, Ligon KL, Rakhlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171-10178. (Pubitemid 44672072)
38. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639. (Pubitemid 46224241)
39. Hemeryck A, Geerts R, Monbaliu J, et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 2007;60:777-787. (Pubitemid 47389383)